IMM 201

Drug Profile

IMM 201

Alternative Names: DAR 901; Heat-killed Mycobacterium vaccae strain NCTC 11659; IMM-201; SRL 172

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Silence Therapeutics
  • Developer Aeras; Geisel School of Medicine; Immodulon Therapeutics; Tokyo Medical and Dental University; University of Colorado at Boulder
  • Class Adjuvants; Antineoplastics; Antivirals; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • Preclinical Post-traumatic stress disorders
  • Discontinued Asthma; Atopic dermatitis; Hepatitis B; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Seasonal allergic rhinitis; Small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in USA (Intradermal, Injection)
  • 21 Jul 2017 Preclinical trials in Post-traumatic stress disorder in USA (Injection) (Immodulon pipeline, July 2017)
  • 21 Jul 2017 Pharmacodynamics data from a preclinical trial in Post-traumatic stress disorder released by Immodulon Therapeutics (Immodulon pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top